Skip to main content
Autobound logo

AbbVie news and events in 2026

AbbVie is a biopharmaceutical organization that discovers and develops medicines and healthcare solutions. The organization focuses its research and production on therapeutic areas including immunology, oncology, neuroscience, eye care, and aesthetics.

Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn

Get AbbVie's live signals in Claude or ChatGPT, or by API

Add to Claude / ChatGPT (MCP)Get an API key: 1,000 free credits
AskWhat changed at AbbVie this week? Use Autobound signals for abbvie.com.
Dated updates
110
Last event
Nov 2, 2026
Open rolesSnapshot Nov 3, 2026
351
Latest SEC filing
Nov 2, 2026

Source: Autobound Signal API · 110 signals tracked for AbbVie · updated

Overview

AbbVie by topic

Latest events

Latest AbbVie events

All AbbVie news →
  1. Revenue
    AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82AbbVie reported third-quarter 2026 revenue of $17.404 billion, an increase of 10.3% year over year.
    tradingview.com
  2. News
    AbbVie Reports Third-Quarter 2026 Financial ResultsWith Apogee Therapeutics
    prnewswire.com
  3. In development
    AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple MyelomaAbbVie submitted a Biologics License Application to the FDA for its multiple myeloma drug candidate etentamig.
    finance.yahoo.com
  4. Launch
    U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseAbbVie announced that the U.S. FDA approved a subcutaneous induction regimen for SKYRIZI for adults with moderately to severely active Crohn's disease.
    prnewswire.com
  5. In development
    AbbVie unveils positive Phase III results for lutikizumabAbbVie published positive Phase III results evaluating the efficacy and safety of its investigational drug lutikizumab.
    marketscreener.com
  6. In development
    AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO ReadoutsAbbVie reported Phase 2a trial data for its investigational dual-targeting Crohn's disease therapy ABBV-466.
    finance.yahoo.com
  7. In development
    AbbVie's subcutaneous risankizumab meets Phase III AFFIRM endpointsAbbVie reported Phase III trial results for its subcutaneous induction regimen of risankizumab (Skyrizi) in patients with Crohn's disease.
    allsci.com
  8. In development
    AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCAbbVie is developing telisotuzumab adizutecan (Temab-A; ABBV-400), an investigational antibody-drug conjugate for CRC and NSCLC which received two FDA Breakthrough Therapy Designations.
    prnewswire.com
  9. In development
    AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly...AbbVie and Genmab announced positive topline results from a Phase 3 trial of their jointly developed drug, epcoritamab, in combination with R-CHOP, for treating newly diagnosed diffuse large B-cell lymphoma (DLBCL).
    prnewswire.com
  10. News
    AbbVie (NYSE:ABBV) Wins FDA Approval for Parkinson's Pill Juvmo as Dermatology Congress OpensWith Cerevel Therapeutics
    kalkinemedia.com

Showing 10 of 33 events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track AbbVie with the Signal API

One POST /v1/companies/enrich call with abbvie.com returns every signal type for AbbVie, each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Same industry

Companies related to AbbVie

AbbVie questions

What is the latest news on AbbVie?
On Oct 30, 2026, tradingview.com reported: AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82. This page tracks 33 news events for AbbVie since Jun 11, 2026, each with a date and a source link.
What is going on with AbbVie?
In the 90 days to Nov 4, 2026, Autobound tracked 25 news events, 6 8-K filings, 4 hiring snapshots, 1 deal, 41 signals for AbbVie. The newest story is from Oct 30, 2026 (Revenue), reported by tradingview.com.
Has AbbVie announced any acquisitions?
The latest deal story is from Aug 29, 2026. ad-hoc-news.de reported: Karuna Therapeutics stock steady with AbbVie deal and schizophrenia drug progress. The acquisitions page lists 1 deal with a source for each.
What else does Autobound track for AbbVie?
Beyond news and filings, Autobound lists 62+ signals for AbbVie from 7 sources: X (Twitter) (15+), Glassdoor (14), LinkedIn (14), Reddit (10), Patents (6), Conference talks (2), Podcasts (1). See the AbbVie signals page for the dated list.
Is AbbVie hiring right now?
Yes. As of Nov 3, 2026, AbbVie had 351 open roles, and Engineering had the most with 22.

Page updated , the date of the newest row on this page.

Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.

Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.

Data as of .

How this data is built →Get it from the Signal API →